Business Description
Cannara Biotech Inc
NAICS : 325410
SIC : 3741
ISIN : CA13765U2002
Total Employee Number:
363Compare
Compare
Traded in other countries / regions
LOVE.CanadaLOVFF.USA8CB0.Germany IPO Date
2019-01-15Description
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.64 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 1.4 | |||||
Interest Coverage | 6.24 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.99 | |||||
Beneish M-Score | -0.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 41.7 | |||||
3-Year EBITDA Growth Rate | 44.2 | |||||
3-Year EPS without NRI Growth Rate | 76.3 | |||||
3-Year Book Growth Rate | 13.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.63 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.02 | |||||
9-Day RSI | 42.86 | |||||
14-Day RSI | 41.44 | |||||
3-1 Month Momentum % | -3.12 | |||||
6-1 Month Momentum % | 1.65 | |||||
12-1 Month Momentum % | 21.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.06 | |||||
Quick Ratio | 1.24 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 282.82 | |||||
Days Sales Outstanding | 46.23 | |||||
Days Payable | 66.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 1.77 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 42.39 | |||||
Operating Margin % | 15.75 | |||||
Net Margin % | 9 | |||||
EBITDA Margin % | 21.65 | |||||
FCF Margin % | 14.22 | |||||
OCF Margin % | 24.42 | |||||
ROE % | 9.65 | |||||
ROA % | 5.94 | |||||
ROIC % | 8.71 | |||||
3-Year ROIIC % | 36.29 | |||||
ROC (Joel Greenblatt) % | 13.27 | |||||
ROCE % | 13.01 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.37 | |||||
Forward PE Ratio | 8.42 | |||||
PE Ratio without NRI | 16.83 | |||||
Price-to-Owner-Earnings | 20.06 | |||||
PS Ratio | 1.48 | |||||
PB Ratio | 1.42 | |||||
Price-to-Tangible-Book | 1.42 | |||||
Price-to-Free-Cash-Flow | 10.09 | |||||
Price-to-Operating-Cash-Flow | 5.95 | |||||
EV-to-EBIT | 9.97 | |||||
EV-to-EBITDA | 7.37 | |||||
EV-to-Revenue | 1.6 | |||||
EV-to-Forward-Revenue | 1.28 | |||||
EV-to-FCF | 11.23 | |||||
Price-to-GF-Value | 1.04 | |||||
Price-to-Graham-Number | 1.07 | |||||
| Price-to-Net-Current-Asset-Value | 5.69 | |||||
Earnings Yield (Greenblatt) % | 10.03 | |||||
FCF Yield % | 9.54 |
Cannara Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cannara Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2023-02-13 | 0.72 (-1.57%) |
Show
Entries
Guru Commentaries on OTCPK:LOVFF
No articles.
Press Release
Articles on Cannara Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers